WO2008079326A3 - Procédés d'utilisation et d'identification de modulateurs de dll4 - Google Patents

Procédés d'utilisation et d'identification de modulateurs de dll4 Download PDF

Info

Publication number
WO2008079326A3
WO2008079326A3 PCT/US2007/026149 US2007026149W WO2008079326A3 WO 2008079326 A3 WO2008079326 A3 WO 2008079326A3 US 2007026149 W US2007026149 W US 2007026149W WO 2008079326 A3 WO2008079326 A3 WO 2008079326A3
Authority
WO
WIPO (PCT)
Prior art keywords
delta
methods
identifying modulators
identifying
modulators
Prior art date
Application number
PCT/US2007/026149
Other languages
English (en)
Other versions
WO2008079326A2 (fr
Inventor
Parkash Gill
Ren Liu
Valery Krasnoperov
Original Assignee
Vasgene Therapeutics Inc
Parkash Gill
Ren Liu
Valery Krasnoperov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasgene Therapeutics Inc, Parkash Gill, Ren Liu, Valery Krasnoperov filed Critical Vasgene Therapeutics Inc
Priority to EP07853456A priority Critical patent/EP2120996A2/fr
Priority to AU2007338734A priority patent/AU2007338734A1/en
Publication of WO2008079326A2 publication Critical patent/WO2008079326A2/fr
Publication of WO2008079326A3 publication Critical patent/WO2008079326A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne pour certains modes de réalisation des procédés d'identification et d'utilisation d'agonistes et d'antagonistes de la signalisation Dll4 (Delta-like 4).
PCT/US2007/026149 2006-12-20 2007-12-20 Procédés d'utilisation et d'identification de modulateurs de dll4 WO2008079326A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07853456A EP2120996A2 (fr) 2006-12-20 2007-12-20 Procédés d'utilisation et d'identification de modulateurs de dll4
AU2007338734A AU2007338734A1 (en) 2006-12-20 2007-12-20 Methods for using and identifying modulators of delta-like 4

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87644406P 2006-12-20 2006-12-20
US60/876,444 2006-12-20
US90175407P 2007-02-16 2007-02-16
US60/901,754 2007-02-16

Publications (2)

Publication Number Publication Date
WO2008079326A2 WO2008079326A2 (fr) 2008-07-03
WO2008079326A3 true WO2008079326A3 (fr) 2008-10-30

Family

ID=39311083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/026149 WO2008079326A2 (fr) 2006-12-20 2007-12-20 Procédés d'utilisation et d'identification de modulateurs de dll4

Country Status (3)

Country Link
EP (1) EP2120996A2 (fr)
AU (1) AU2007338734A1 (fr)
WO (1) WO2008079326A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
EP2066694B1 (fr) 2006-09-29 2015-11-04 Oncomed Pharmaceuticals, Inc. Compositions et procédés permettant de diagnostiquer et de traiter le cancer
EP2282769A4 (fr) 2008-04-29 2012-04-25 Abbott Lab Immunoglobulines à double domaine variable et utilisations
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP2297209A4 (fr) 2008-06-03 2012-08-01 Abbott Lab Immunoglobulines à deux domaines variables et leurs utilisations
EP2321422A4 (fr) 2008-07-08 2013-06-19 Abbvie Inc Immunoglobulines à double domaine variable de prostaglandine e2 et leurs utilisations
JP5560270B2 (ja) 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ結合剤およびアンタゴニストならびにその使用方法
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011047262A2 (fr) 2009-10-15 2011-04-21 Abbott Laboratories Immunoglobulines à deux domaines variables et utilisations afférentes
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
ES2561102T3 (es) 2010-01-13 2016-02-24 Oncomed Pharmaceuticals, Inc. Agentes de unión a Notch1 y procedimientos de uso de los mismos
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
CA2809433A1 (fr) 2010-08-26 2012-03-01 Abbvie Inc. Immunoglobulines a deux domaines variables et leurs utilisations
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
BR112015009961B1 (pt) 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
WO2014144280A2 (fr) 2013-03-15 2014-09-18 Abbvie Inc. Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1β et/ou il -17
EP3212233B1 (fr) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004669A1 (fr) * 1997-05-14 2000-05-31 Asahi Kasei Kogyo Kabushiki Kaisha Nouvel inhibiteur de differentiation
WO2007070671A2 (fr) * 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004669A1 (fr) * 1997-05-14 2000-05-31 Asahi Kasei Kogyo Kabushiki Kaisha Nouvel inhibiteur de differentiation
WO2007070671A2 (fr) * 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOGUERA-TROISE IRENE ET AL: "Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.", NATURE 21 DEC 2006, vol. 444, no. 7122, 21 December 2006 (2006-12-21), pages 1032 - 1037, XP002489427, ISSN: 1476-4687 *
RIDGWAY JOHN ET AL: "Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.", NATURE 21 DEC 2006, vol. 444, no. 7122, 21 December 2006 (2006-12-21), pages 1083 - 1087, XP002489428, ISSN: 1476-4687 *

Also Published As

Publication number Publication date
WO2008079326A2 (fr) 2008-07-03
EP2120996A2 (fr) 2009-11-25
AU2007338734A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
WO2008079326A3 (fr) Procédés d'utilisation et d'identification de modulateurs de dll4
WO2007028110A3 (fr) Methodes d'utilisation et d'identification de modulateurs de delta-like 4
WO2009085209A3 (fr) Méthodes d'utilisation et d'identification de modulateurs de delta-like 4
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
WO2008033408A3 (fr) Procédés d'identification de composés qui modulent la signalisation cellulaire et procédés employant de tels composés
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
WO2007081740A3 (fr) Méthodes et compositions basés sur des micro-arn et s'appliquant au diagnostic et au traitement de cancers solides
WO2007056681A3 (fr) Procedes d'administration d'agents hypoglycemiques
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d'utilisation
WO2009009173A3 (fr) Klotho bêta
MX2010004374A (es) Armazones proteinicos.
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
WO2009044173A3 (fr) Procédés de traitement du cancer à l'aide d'inhibiteurs de la voie de notch
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
TN2009000181A1 (en) Agonist trkb antibodies and uses thereof
SG161281A1 (en) Hgf beta chain variants
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
TW200833842A (en) Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
WO2007076174A3 (fr) Procédés, systèmes et dispositif pour marqueurs multidomaines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07853456

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007338734

Country of ref document: AU

Ref document number: 2007853456

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007338734

Country of ref document: AU

Date of ref document: 20071220

Kind code of ref document: A